Netherlands detects a case of thrombosis after injection with AstraZeneca against coronavirus

The center that records the side effects of vaccines, Lareb, received a report on Thursday morning about a suspected thrombosis after an injection with a vaccine against covid-19 of AstraZeneca, although it stressed that it is not a serious incident, nor does it require hospitalization.

Lareb said it will investigate this case in depth, after Denmark today suspended for 14 days the use of the AstraZeneca vaccine after registering “serious cases of thrombi” in people who had received it, one of the cases is related to a death, although he stressed that it still cannot be concluded that there is a direct relationship between the vaccine and the thrombi.

This decision of Denmark comes less than a day after the EMA has ensured that, after a preliminary analysis, it does not believe that there is “a specific problem” with a batch of AstraZeneca withdrawn by Austria as a precautionary measure after the death of a person diagnosed with multiple thrombosis – formation of blood clots – and the disease of another coinciding with their vaccination.

The Ministry of Health and the Institute of Public Health of Netherlands They are studying the information that comes from Denmark, before making any decision about the suspension or continuity of the use of this vaccine.

AstraZeneca Netherlands  told Dutch television NOS today that it is in close contact with the Amsterdam-based EMA, and recalled that it is this European regulator who decides on the practical consequences of the reported clotting problems in vaccinated people.

“It is not up to us to decide or advise on the use of vaccines, that’s what the health authorities are for”, underlined AstraZeneca Netherlands.

The EMA assured yesterday that “currently, there are no indications that vaccination has caused these conditions, which are not listed as side effects with this vaccine,” nor were similar cases detected in clinical trials carried out by the laboratory, therefore that he considers a quality defect unlikely, although he is “looking into the quality” of that particular lot, the ABV5300.

The EMA Safety Committee (PRAC) is reviewing the reported cases of conditions and all cases of thromboembolic events and conditions related to blood clots that have been reported by patients coinciding with the days after vaccination.